One of my high Vimpat prescribers asked me if we are launching the nasal midazolam we bought? He is concerned about the respiratory depression and the test doses, but he knows nothing more. I cannot get any answers from my Manager either Has anyone heard anything?
Depends how long it takes to respond to the CRL. Tell him to wait and see what’s in the label regarding these issues before he gets his Vimpanties in a wad.
We are launching Midazolam as this provides an unmet for intended rescue treatment for acute repetitive seizures (ARS, also known as serial, recurrent or cluster seizures) in patients with epilepsy. UCB was reviewing to in-license this as far back as 2014 and really should have in-licensed it then. There is a huge unmet need for hospital rescue medication and as UCB is THE EPILEPSY COMPANY (loud and proud), as a patient value company (unlike the wacky idiots in the EMA and US office of Eisai who know nothing about patient centricity efforts will lead to direct sales of your medication, despite it being difficult to directly correlate). UCB is a truly patient centric company and I am proud to work here.
Any truth in the rumor the FDA is looking into the our speaker program for potential kickback violations?
Don’t worry, that was all to enhance patient value. Our speakers are simply trying to spread the voice of the patient.
Compliance, Marketing and Sales leadership in atlanta know all about it. Probably trying to let it play out hence the radio silence from leadership